Short answer
ANAVEX LIFE SCIENCES CORP. (AVXL) filed its Q1 2026 10-Q quarterly report on Aug 28, 2026 for the quarter ended Mar 31, 2026.
Q1 2026 key financials · XBRL
- Net income
- −$5M
- +52.3% YoY · +6.0% QoQ
- EPS (diluted)
- −$0.06
- +53.8% YoY · +0.0% QoQ
Source: XBRL data from the ANAVEX LIFE SCIENCES CORP. (AVXL) Q1 2026 10-Q on SEC EDGAR. USD.
ANAVEX LIFE SCIENCES CORP. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0, unchanged YoY; no products approved for commercial sale
- Profitability and margins not disclosed; clinical-stage company with no revenue
- Lead program ANAVEX 2-73 prioritized; other assets development paused
- Near-term focus on FDA engagement and data-driven regulatory strategy
- Headwinds: material internal-control weakness, Nasdaq compliance, funding needs, and CEO-related litigation risks
Risk Factors
- Former CEO termination for Cause triggered potential FDA, SEC, Nasdaq, and other enforcement actions
- Former CEO arbitration demand and New York fiduciary-duty lawsuit created ongoing litigation exposure
- Special Committee review increased management distraction, costs, and reputational harm
- Investor, clinical-investigator, patient, and business-partner confidence risk following leadership misconduct findings
- Common-stock market-price risk from proceedings involving the former CEO and independent directors
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other ANAVEX LIFE SCIENCES CORP. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.